Treat and Extend versusPro Re Nataregimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study
Author:
Affiliation:
1. Vista Klinik; Binningen Switzerland
2. Department of Ophthalmology; Kantonsspital Liestal Switzerland
3. University of Basel; Basel Switzerland
Funder
Novartis Pharma
Publisher
Wiley
Subject
Ophthalmology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/aos.13031/fullpdf
Reference31 articles.
1. Anti-VEGF treatment in neovascular age-related macular degeneration. A treat-and-extend protocol over 2 years;Abedi;Retina,2014
2. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2;Abraham;Am J Ophthalmol,2010
3. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol;Berg;Ophthalmology,2015
4. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration;Boyer;Ophthalmology,2009
5. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;N Engl J Med,2006
Cited by 57 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration;Ophthalmology Retina;2023-10
2. The role of mitochondrial genes on nuclear gene expression in neovascular age related macular degeneration: analysis of nuclear VEGF gene expression after ranibizumab treatment in cytoplasmic hybrid retinal pigment epithelial cell lines correlated with clinical evolution;International Journal of Retina and Vitreous;2023-07-25
3. Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence;Clinical Ophthalmology;2023-04
4. Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis;Eye;2023-03-01
5. STRICT PRO RE NATA VERSUS TREAT-AND-EXTEND REGIMENS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION;Retina;2023-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3